Scope
The AAD focused update adds a field-directed treatment option for actinic keratosis. The available official highlights distinguish this addition from the established background recommendations.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Focused treatment addition
- The focused update gives a strong recommendation for tirbanibulin as field therapy for actinic keratosis. [1]
Background guidance retained on the source page
- The background guideline strongly recommends ultraviolet protection, cryosurgery, topical imiquimod and fluorouracil. Photodynamic therapy and diclofenac have conditional recommendations, including individual treatment and combination regimens. [1]
Limitations and use
- This covers the official recommendation highlights, including the focused tirbanibulin addition. It does not provide the treatment regimen, patient-selection criteria or complete evidence rationale. Background recommendations on the same page should not be presented as newly issued in the focused update.
- This House summary is based on the linked focused or condensed recommendation sources; it does not represent the complete original publication.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Actinic keratosis: focused update — focused recommendation source
Selected recommendation material consulted
Publication details
- Issuing organisation
- AAD
- Resource type
- Clinical practice guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.